Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug;26(4):486-92.
doi: 10.3978/j.issn.1000-9604.2014.08.10.

Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review

Min Yan  1 , Hui-Min Lv  1 , Meng-Wei Zhang  1 , Shu-De Cui  1
Affiliations

Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review

Min Yan et al. Chin J Cancer Res. 2014 Aug.

Abstract

Molecular subtyping of breast cancer may provide additional prognostic information regarding patient outcome. The epidermal growth factor receptor (HER2) overexpressing breast cancers are designated as HER2-postive (HER2+) breast cancer and carry a particularly unfavorable prognosis. We present two cases of HER2-postive metastatic breast cancer (MBC) who are found to be a challenge to treat, especially due to the occurrence of brain metastasis. Trastuzumab-based therapy improves clinical outcomes, even if the patient has undergone multi-line treatment. These case reports also emphasize the importance of retesting HER2 status because it can be discordance in receptor status between primary and recurrent breast cancer.

Keywords: Breast cancer; brain metastasis; trastuzumab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The brain MRI (A and B) and liver CT (C and D) before and after the treatment of Xeloda.
Figure 2
Figure 2
The brain MRI (A and B) and liver CT (C and D) before and after the treatment of Xeloda combine with Herceptin.
See this image and copyright information in PMC

References

    1. Lohmann AE, Saini KS, Metzger-Filho O. Pertuzumab in metastatic breast cancer: unanswered questions. Transl Cancer Res 2012;1:122-4
    1. Nelson V, Rademaker A, Kaklamani V.Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant. Chin Clin Oncol 2013;2:10 - PubMed
    1. Christinat A, Di Lascio S, Pagani O.Hormonal therapies in young breast cancer patients: when, what and for how long? J Thorac Dis 2013;5:S36-46 - PMC - PubMed
    1. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242-52 - PubMed
    1. Alba E, Ruiz-Borrego M, Margelí M, et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat 2010;122:169-76 - PubMed